Trans-resveratrol's Influence on the Development of CHF in Early Postmenopausal Women with HTN and Reduced BMD

What this trial studies

1. To measure the ability of trans-resveratrol to influence the development of chronic heart failure (CHF) in women in the early postmenopausal period (1-4 years) with hypertension (HTN) and reduced bone mineral density (BMD). 2. To evaluate the safety of long-term use of trans-resveratrol in an amount of 500 mg per day.

Conditions in scope

• Heart Failure
• Arterial Hypertension
• Osteopenia
• Menopause

Interventions

• Trans-resveratrol extract from Polygonum Cuspidatum (Dietary Supplement) — Trans-resveratrol extract from Polygonum Cuspidatum
• Placebo (Other) — Placebo

Who can join

Women only · Ages 45 Years to 55 Years

Inclusion criteria

• availability of a signed Informed Consent (Information Sheet) of the patient to participate in the clinical trial;
• female patients in the postmenopausal period (1-4 years) with hypertension (stage I-II, stage I-II), which is established according to the classification of arterial hypertension (HTN) by stages, degrees and cardiovascular risk.
• Accordingly, the indicators SBP within 140 - 159 mmHg, DBP 90 - 99 mmHg - HTN stage I;
• SBP within 160 - 179 mmHg, DBP 100 - 109 mmHg - HTN stage II. Depending on the damage to target organs:
• Stage I - objective signs of organic damage to target organs are absent; Stage II - there are objective signs of target organ damage without symptoms or dysfunction: LV hypertrophy (according to ECG, Echo-CG, MRI).
• reduced bone mineral density (BMD), which meets the criteria for osteopenia of the I-III degree, established by ultrasound densitometry: osteopenia of the I degree T-score from -1.0 to -1.5, II degree T-score from -1.5 to -2.0, III degree T-score from -2.0 to -2.5;
• patient's readiness for adequate cooperation in the process of clinical trials.

Exclusion criteria

• diagnosed congenital or acquired heart defects;
• established non-coronary myocardial diseases (myocarditis, cardiomyopathy);
• rhythm or conduction disorders with concomitant hemodynamic disorders (extrasystoles, paroxysmal tachycardias, atrial fibrillation/flutter, AV block 2 and 3 degrees);
• endocrine diseases, blood system diseases, systemic connective tissue diseases;
• diagnosed chronic obstructive pulmonary disease;
• impaired renal function (glomerular filtration rate according to the CKD-EPI formula less than 60 ml/min), liver.
• verified oncological diseases;
• abnormal uterine bleeding, endometriosis, pelvic inflammatory diseases;

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Active, not recruiting
• Study type: Interventional
• Phase: N/A
• Start date: 2024-09-09
• Primary completion: 2025-02-09
• Last update posted: 2025-03-19
• First posted: 2025-02-14

Sponsor & contact

Lead sponsor: OMNIFARMA LLC (Industry)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• To measure the influence of trans-resveratrol on a development of chronic heart failure in early postmenopausal women period (1-4 years) with arterial hypertension and decreased bone mineral density (From enrollment to the end of treatment (3 month for each patient))
  * Percentage of patients in whom the use of 500 mg trans-resveratrol daily contributed to the normalization of laboratory and instrumental parameters; * Percentage of patients in whom the use of 500 mg trans-resveratrol daily contributed to the normalization of quality of life (according to the MENQOL and EuroQol-5D-3L questionnaires); * Percentage of patients in whom the use of 500…
• The safety of long-term using of trans-resveratrol in the amount of 500 mg per day (From enrollment to the end of treatment (3 month for each patient))
  The level of adverse events that does not exceed 5% of the sample size (N=50).

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.